MediWound Ltd

MediWound Ltd, based in Israel, is a biotechnology company specializing in innovative enzymatic therapeutics for wound care, focusing on advanced treatments for burn injuries and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, MediWound Ltd focuses on developing and commercializing therapeutic solutions for wound care. The company has pursued various funding initiatives, including a PIPE round in which they raised USD 25. 00 mn led by Mölnlycke Health Care AB.

MediWound has successfully completed 10 deals to date, with the most recent deal occurring on March 20, 2014. The company's leadership includes CEO Ofer Gonen, while Lior Rosenberg is noted as a key founder. MediWound Ltd. specializes in innovative enzymatic therapeutics focused on non-surgical tissue repair.

The company's core product offerings include NexoBrid®, a biological product that enzymatically removes nonviable burn tissue, or eschar, allowing for effective treatment of deep partial and full-thickness thermal burns without damaging viable tissue. NexoBrid has been successfully approved in over 40 countries, including the United States, European Union, and Japan, serving healthcare providers and hospitals in emergency and burn care settings. Additionally, the company is advancing EscharEx®, a bioactive, multimodal debridement therapy for chronic and hard-to-heal wounds, which is in the late stages of clinical development and targets venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs). MW005 is another product in development aimed at treating low-risk Basal Cell Carcinoma (BCC).

MediWound operates in various geographical markets, including North America, Europe, and Asia, reflecting a robust global outreach strategy. MediWound generates revenue primarily through sales of its flagship products, NexoBrid® and EscharEx®, to healthcare facilities, hospitals, and medical distributors. In the most recent year, 2021, the company reported revenue of USD 23. 76 mn and an EBITDA loss of USD 9.

98 mn. Transactions typically occur through direct sales and partnerships with biopharmaceutical companies for distribution, such as the collaboration with Vericel Corporation for the U. S. commercial launch of NexoBrid.

The pricing structure for these products is established based on market demand and regulatory approvals, reflecting the specialized nature of the therapeutic solutions provided to healthcare professionals and patients. The company’s financial performance is closely tied to the success of its product launches and ongoing clinical trials, as well as the expansion of its market presence globally. MediWound Ltd plans to leverage recent funding to advance its product pipeline and expand its market reach. The company is focused on launching new products, including MW005, targeted at treating low-risk Basal Cell Carcinoma (BCC).

Additionally, MediWound aims to expedite the commercialization of EscharEx® for chronic wounds. The company is also looking to expand into emerging markets across Asia and South America by 2025, supported by its recent funding round, which raised USD 25. 00 mn through a PIPE deal, ensuring sufficient capital for these strategic initiatives.